0001232524-17-000113.txt : 20170512
0001232524-17-000113.hdr.sgml : 20170512
20170512191427
ACCESSION NUMBER: 0001232524-17-000113
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170511
FILED AS OF DATE: 20170512
DATE AS OF CHANGE: 20170512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jazz Pharmaceuticals plc
CENTRAL INDEX KEY: 0001232524
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 981032470
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: FIFTH FLOOR, WATERLOO EXCHANGE
STREET 2: WATERLOO ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
BUSINESS PHONE: 353-1-634-7800
MAIL ADDRESS:
STREET 1: FIFTH FLOOR, WATERLOO EXCHANGE
STREET 2: WATERLOO ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
FORMER COMPANY:
FORMER CONFORMED NAME: JAZZ PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030513
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: COZADD BRUCE C
CENTRAL INDEX KEY: 0001193210
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33500
FILM NUMBER: 17840607
MAIL ADDRESS:
STREET 1: C/O JAZZ PHARMACEUTICALS PLC
STREET 2: 5TH FL, WATERLOO EXCHANGE, WATERLOO RD
CITY: DUBLIN L2 4
STATE: L2
ZIP: 00000
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2017-05-11
0
0001232524
Jazz Pharmaceuticals plc
JAZZ
0001193210
COZADD BRUCE C
5TH FL, WATERLOO EXCHANGE
WATERLOO RD
DUBLIN 4
L2
IRELAND
1
1
0
0
Chairman & CEO
Ordinary Shares
2017-05-11
4
S
0
12073
153.1694
D
296418
D
Ordinary Shares
2017-05-11
4
S
0
17927
153.675
D
278491
D
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $152.5200 to $153.5150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $153.5200 to $154.0400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
By: /s/Peter A Christou, as attorney in fact For: Bruce C. Cozadd
2017-05-12